MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.


Journal

Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535

Informations de publication

Date de publication:
09 2019
Historique:
received: 10 07 2018
revised: 16 01 2019
accepted: 17 06 2019
pubmed: 23 6 2019
medline: 18 6 2020
entrez: 23 6 2019
Statut: ppublish

Résumé

CD205 is a type I transmembrane glycoprotein and is a member of the C-type lectin receptor family. Analysis by mass spectrometry revealed that CD205 was robustly expressed and highly prevalent in a variety of solid malignancies from different histotypes. IHC confirmed the increased expression of CD205 in pancreatic, bladder, and triple-negative breast cancer (TNBC) compared with that in the corresponding normal tissues. Using immunofluorescence microscopy, rapid internalization of the CD205 antigen was observed. These results supported the development of MEN1309/OBT076, a fully humanized CD205-targeting mAb conjugated to DM4, a potent maytansinoid derivate, via a cleavable N-succinimidyl-4-(2-pyridyldithio) butanoate linker. MEN1309/OBT076 was characterized

Identifiants

pubmed: 31227646
pii: 1535-7163.MCT-18-0624
doi: 10.1158/1535-7163.MCT-18-0624
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antigens, CD 0
DEC-205 receptor 0
Immunoconjugates 0
Lectins, C-Type 0
Minor Histocompatibility Antigens 0
Receptors, Cell Surface 0
Maytansine 14083FR882

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1533-1543

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Giuseppe Merlino (G)

Department of Experimental and Translational Oncology, Menarini Ricerche SpA, Pomezia, Rome, Italy. gmerlino@menarini-ricerche.it.

Alessio Fiascarelli (A)

Department of Experimental and Translational Oncology, Menarini Ricerche SpA, Pomezia, Rome, Italy.

Mario Bigioni (M)

Department of Experimental and Translational Oncology, Menarini Ricerche SpA, Pomezia, Rome, Italy.

Alessandro Bressan (A)

Department of Experimental and Translational Oncology, Menarini Ricerche SpA, Pomezia, Rome, Italy.

Corrado Carrisi (C)

Department of Experimental and Translational Oncology, Menarini Ricerche SpA, Pomezia, Rome, Italy.

Daniela Bellarosa (D)

Department of Experimental and Translational Oncology, Menarini Ricerche SpA, Pomezia, Rome, Italy.

Massimiliano Salerno (M)

Department of Experimental and Translational Oncology, Menarini Ricerche SpA, Pomezia, Rome, Italy.

Rossana Bugianesi (R)

Department of Pharmacokinetics and Metabolism, Menarini Ricerche, Pomezia, Rome, Italy.

Rosanna Manno (R)

Research Toxicology Center, Pomezia, Rome, Italy.

Cristina Bernadó Morales (C)

Preclinical Research Program, Vall D'Hebron, Institute of Oncology and Centro de Investigación Biomédica en Red en Oncologia (CIBERONC), Barcelona, Spain.

Joaquin Arribas (J)

Preclinical Research Program, Vall D'Hebron, Institute of Oncology and Centro de Investigación Biomédica en Red en Oncologia (CIBERONC), Barcelona, Spain.
Department of Biochemistry and Molecular Biology, Universitat Autonoma de Barcelona, Campus de la UAB, Bellaterra, Spain.
Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

Rachel L Dusek (RL)

Oxford BioTherapeutics, Ltd., Abingdon, United Kingdom.

James E Ackroyd (JE)

Oxford BioTherapeutics, Ltd., Abingdon, United Kingdom.

Phuoc Huy Pham (PH)

Oxford BioTherapeutics, Ltd., Abingdon, United Kingdom.

Rahel Awdew (R)

Oxford BioTherapeutics, Ltd., Abingdon, United Kingdom.

Dee Aud (D)

Oxford BioTherapeutics, Ltd., Abingdon, United Kingdom.

Michael Trang (M)

Oxford BioTherapeutics, Ltd., Abingdon, United Kingdom.

Carmel M Lynch (CM)

Oxford BioTherapeutics, Ltd., Abingdon, United Kingdom.

Jonathan Terrett (J)

Oxford BioTherapeutics, Ltd., Abingdon, United Kingdom.

Keith E Wilson (KE)

Oxford BioTherapeutics, Ltd., Abingdon, United Kingdom.

Christian Rohlff (C)

Oxford BioTherapeutics, Ltd., Abingdon, United Kingdom.

Stefano Manzini (S)

Menarini Ricerche S.p.A - Menarini Group, Florence, Italy.

Andrea Pellacani (A)

Menarini Ricerche S.p.A - Menarini Group, Florence, Italy.

Monica Binaschi (M)

Department of Experimental and Translational Oncology, Menarini Ricerche SpA, Pomezia, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH